Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Incyte Corporation
Eli Lilly and Company
Medical University of South Carolina
University of Alabama at Birmingham
BioNTech SE
QED Therapeutics, a BridgeBio company
Academic and Community Cancer Research United
EpicentRx, Inc.
EMD Serono
PCI Biotech AS
Washington University School of Medicine
Concordia Laboratories Inc.
Hellenic Cooperative Oncology Group
Allina Health System
New Mexico Cancer Research Alliance
University of Miami
Stanford University
University of Utah
Emory University